Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites

Clinical Pharmacokinetics

Volumn 40, Issue 1, 2001, Pages 41-62

  Kerbusch, T ^a   De Kraker, J ^b   Keizer, H J ^c   Van Putten, J W G ^d   Groen, H J M ^d   Jansen, R L H ^e   Schellens, J H M ^a   Beijnen, J H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DRUG METABOLITE; IFOSFAMIDE; METHYLENE BLUE;

ALOPECIA; AREA UNDER THE CURVE; BLOOD TOXICITY; BRAIN DISEASE; CHIRALITY; CYTOTOXICITY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG STRUCTURE; HEMORRHAGIC CYSTITIS; HUMAN; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FANCONI SYNDROME; HUMANS; IFOSFAMIDE; METHYLENE BLUE; NEUROTOXICITY SYNDROMES; STEREOISOMERISM;

EID: 0035114572     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140010-00004     Document Type: Review

References (211)

1. Ifosfamide/mesna: A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer
2. Basis and new development in the field of oxazaphosphorines
3. Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumour therapeutic agent
4. Alkylating agents, antimetabolites, hormones and other antiproliferative agents
5. The initial clinical trial of nitrogen mustard
6. The history of ifosfamide
7. Ifosfamide: Should the honeymoon be over?
8. Oxazaphosphorine cytostatics: Past-present-future
9. Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium “mesnum” in patients with advanced carcinoma
10. Ifosfamide
11. Metabolism of oxazaphosphorine
12. Formation of chloroethylamine and 1,3-oxazolidine-2-one following ifosfamide administration in humans
13. Studies on the metabolism of isophosphamide “NSC-109724” in man
14. Renal clearance of ifosfamide
15. Role of CYP in oxazaphosphorine metabolism: Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450
16. Activation of the anticancer drug ifosphamide by rat liver microsomal P450 enzymes
17. Modulation of P450-dependent ifosfamide pharmacokinetics: A better understanding of drug activation in vivo
18. In-vitro metabolism of anticancer drugs, methods and applications: Paclitaxel, docetaxel, tamoxifen and ifosfamide
19. Efficacy and toxicity of ifosfamide stereoisomers in an in vivo rat mammary carcinoma model
20. Differential activation of cyclophosphamide and ifosfamide by cytochrome P-450 2B and 3A in human liver microsomes
21. Identification of the major human hepatic CYP involved in the activation and N-dechloroethylation of ifosfamide
22. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles
23. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of “R”- and “S”ifosfamide in human liver microsomes
24. Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6 Favorable metabolic properties of R-enantiomer
25. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide
26. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene
27. Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans
28. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: Development of a combined chemotherapy/cancer gene therapy strategy
29. Cytochrome P450-based cancer gene therapy, recent advances and future prospects
30. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: Response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines
31. Phenytoin-induced alteration in the N-dechloroethylation of ifosfamide stereoisomers
32. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: Implications for drug interactions
33. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
34. Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with brochogenic carcinoma
35. Time course of enzyme induction in humans: Effect of pentobarbital on nortriptyline metabolism
36. Pharmacokinetic model to describe self-induced decreases in steady-state concentrations of carbamazepine
37. Decreased half-life of ifosfamide “I” after daily oral administration of ifosfamide
38. Macrolide antibiotics inhibit the degradation of the glucocorticoid-responsive cytochrome P450P in rat hepatocytes in vivo and in primary monolayer culture
39. Cytochrome P-450 spin state, inorganic biochemistry of haem iron ligation and functional significance
40. Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism
41. Preferential location of circulating activated cyclophosphamide within the erythrocyte
42. Erythrocytes and the transport of drugs and endogenous compounds
43. Activated oxazaphosphorines are transported predominantly by erythrocytes
44. Partitioning of ifosfamide and its metabolites between red blood cells and plasma
45. Kinetics of cyclophosphamide bio-transformation in vivo
46. Characterisation and quantitative estimation of activated cyclophosphamide in blood and urine
47. Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide
48. Chromatographic analysis of anticancer drugs
49. The analysis of ifosfamide and its metabolites
50. The effect of route of administration and fractionation of dose on the metabolism of ifosfamide
51. Combined thin-layer chromatography-photography-densitometry for the quantification of ifosfamide and its principal metabolites in urine, cerebrospinal fluid and plasma
52. Magnetic resonance spectroscopy studies of ifosfamide in vivo
53. Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy
54. 31P nuclear magnetic resonance spectroscopy
55. Rapid method for the determination of ifosfamide and cyclophosphamide in plasma by high-performance liquid chromatography with solid-phase extraction
56. A simple quantitative HPLC assay for ifosfamide in biological fluids
57. Determination of ifosfamide by HPLC using on-line sample pretreatment
58. Determination of urinary 2- and 3-dechloroethylated metabolites of ifosfamide by high-performance liquid chromatography
59. Enantiomeric separation of R- and Sifosfamide and their determination in serum from clinical subjects
60. Analytical and preparative high-performance liquid chromatographic separation of the enantiomers of ifosfamide, cyclophosphamide and trofosfamide and their determination in plasma
61. Determination of chloroacetaldehyde, a metabolite of oxazaphosphorine cytostatic drugs, in plasma
62. Determination of 4-hydroxyifosfamide in biological matrices by high-performance liquid chromatography
63. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy
64. High-performance liquid chromatographic determination of stabilized 4-hydroxyifosfamide in human plasma and erythrocytes
65. Analysis of ifosforamide mustard, the active metabolite of ifosfamide, in plasma
66. Simultaneous determination of ifosfamide and its metabolite ifosforamide mustard in human plasma by high-performance liquid chromatography
67. Determination of ifosfamide in plasma by gas chromatography with nitrogen detector
68. Rapid gas chromatographic determination of ifosfamide in biological fluids
69. The determination of 2- and 3-dechloroethylifosfamide in plasma and urine
70. Determination of ifosfamide and its 2- and 3-dechloroethylated metabolites using gas chromatography, comparing nitrogen-phosphorous selective and ion-trap mass spectrometry detection
71. Chromatographic analysis of the enantiomers of ifosfamide and some of its metabolites in plasma and urine
72. Determination of 4-hydroxyifosfamide concomitantly with ifosfamide and its dechloroethylated metabolites using gas chromatography and a nitrogen phosphorus-selective detecton
73. Quantification by gas chromatography of N, N′-di-“2-chloroethyl”-phosphordiamidic acid in the plasma of patients receiving isophosphamide
74. Gas chromatographic method for the determination of plasma isophosphamide “NSC-109724”
75. Identification and quantification of metabolite conjugates of activated cyclophosphamide and ifosfamide with mesna in urine by ion-pair extraction and fast atom bombardment mass spectrometry
76. Determination of ifosfamide by gas chromatography-mass spectrometry
77. Determination of iphosphamide and seven metabolites in blood plasma, as stable trifluoroacetyl derivatives by electron capture chemical ionization GC-MS
78. The determination of “-”-“S”- and “+”-“R”ifosfamide in plasma using enantioselective gas chromatography: A validated assay for pharmacokinetic and clinical studies
79. Determination of the enantiomers of ifosfamide and its 2- and 3-Ndechloroethylated metabolites in plasma and urine using enantioselective gas chromatography with mass spectrometric detection
80. Analysis of ifosfamide, 4-hydroxyifosfamide, N2-dechloroethylifosfamide, N3-dechloroethylifosfamide and iphosphoramide mustard in plasma by gas chromatography-mass spectrometry
81. Capillary chromatography in cancer research
82. Capillary gas chromatographic determination of ifosfamide in microvolumes of urine and plasma
83. Ifosfamide metabolism and pharmacokinetics
84. Pharmacokinetics of divided-dose ifosfamide
85. Pharmacokinetics of ifosfamide
86. The bioavailability of oral and intravenous ifosfamide in the treatment of bronchogenic carcinoma
87. Pharmacokinetic studies in lung cancer patients
88. Bioavailability of ifosfamide in patients with bronchial carcinoma
89. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: A pharmacokinefic study in advanced sarcoma patients
90. Disposition of ifosfamide in patients receiving ifosfamide infusion therapy for the treatment of cervical carcinoma
91. Time dependent ifosfamide half-life and metabolism when given as a fractionated regime over 5 days to treat thoracic neoplasms
92. The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients
93. A study of 5 day fractionated ifosfamide pharmacokinetics in consecutive treatment cycles
94. Pharmacokinetics and bioavailability of oral ifosfamide
95. Clinical pharmacokinetics of ifosfamide in combination with N-acetylcysteine
96. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy
97. Ifosfamide and carboplatin combined with 41.8°C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma
98. Metabolism of ifosfamide during a 3 day infusion
99. Pharmacokinetics of ifosfamide and its enantiomers following a single 1h intravenous infusion of the racemate in patients with small cell lung carcinoma
100. Pharmacokinetics, metabolism and clinical effects of ifosfamide in breast cancer patients
101. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide
102. Pharmacokinetics of enantiomers of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma, urine and cerebrospinal fluid
103. Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated metabolites in female cancer patients
104. The N-dechloroethylation of ifosfamide: Using stereochemistry to obtain an accurate picture of a clinically relevant metabolic pathway
105. Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas
106. The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: A randomized cross-over study
107. The effect of age on the pharmacokinetics of ifosfamide
108. Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution
109. 2
110. Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children
111. Comparison of continuous infusion and bolus administration of ifosfamide in children
112. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration
113. The pharmacokinetics of the auto-induction of ifosfamide metabolism during continuous infusion
114. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion
115. Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children
116. Ifosfamide enantiomers: Pharmacokinetics in children
117. Population PK of IFF and its DCE metabolites in children using an enantiospecific PK model
118. Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children
119. Pharmacokinetics of ifosfamide and some metabolites in children
120. Metabolism and pharmacokinetics of oral and intravenous ifosfamide
121. Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients
122. Ifosfamide continuous infusion without mesna
123. Alkylating agent resistance. In vitro studies with human cell lines
124. High-dose ifosfamide for soft tissue sarcomas: Set the scene, or senescence?
125. Effect of chirality on pharmacokinetics and pharmacodynamics
126. Stereoselective separations of chiral anticancer drugs and their application to pharmacodynamic and pharmacokinetic studies
127. Interindividual variations in drug disposition: Clinical implications and methods of investigation
128. Immunohistochemical localization of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue
129. Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms' tumor
130. Ifosfamide clinical pharmacokinetics
131. Etude pharmacoinetique plasmique et de l'elimination de l'ifosfamide en situation de drainage biliarie complet
132. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients
133. Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM
134. A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5′-d“GAC”
135. The oxazaphosphorines
136. Measurement of DNA cross-linking in patients on ifosfamide therapy using single cell gel electrophoresis “Comet” assay
137. Drug resistance in the treatment of sarcomas
138. Ifosfamide induced stress response in human lymphocytes
139. The effect of ifosfamide and its metabolites on intracellular gluthatione levels in vitro and in vivo
140. Mode of action of ifosfamide: New aspects
141. Ifosfamide cytotoxicity on human tumor and renal cells: Role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide
142. Cytotoxicity, DNA cross-linking and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells
143. The comparative pharmacology of cyclophosphamide and ifosfamide
144. High-dose chemotherapy regimens for solid tumors
145. 31P NMR studies of the kinetics of bisalkylation by isophosphoramide mustard: Comparison with phosphoramide mustard
146. The mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin
147. Ifosfamide - Pharmacology, safety and therapeutic potential
148. Toxicity of single-vs fractionated-dose ifosfamide in non-small cell lung cancer: A multi-center study
149. Ifosfamide extrapyramidal neurotoxicity
150. Ifosfamide extrapyramidal neurotoxicity
151. The enigma of ifosfamide encephalopathy
152. Ifosfamide encephalopathy
153. Ifosfamide causes a diazepam-sensitive encephalopathy
154. Hallucinations and ifosfamide-induced neurotoxicity
155. Irreversible encephalopathy with ifosfamide-mesna
156. Fatal encephalopathy with ifosfamide-mesna
157. Central nervous system toxicity following treatment of pediatric patients with ifosfamide/mesna
158. Ifosfamide-induced neurotoxicity: A case report and review of the literature
159. Ifosfamide encephalopathy: A reappraisal
160. Prediction of ifosfamide/mesna associated encephalopathy
161. Ifosfamide encephalopathy and methylene-blue: A case report
162. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum“II” therapy
163. Ifosfamide/mesna and encephalopathy
164. Ifosfamide pharmacokinetics and neurotoxicity
165. Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children
166. Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children: A comment
167. Dechloroethylation of ifosfamide and neurotoxicity
168. Ifosfamide stereoselective dechloroethylation and neurotoxicity
169. Ifosfamide by continuous infusion to prevent encephalopathy
170. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy
171. 2-Chloroacetaldehyde-induced cerebral gluthatione depletion and neurotoxicity
172. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue
173. Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats
174. Inhibition of “mono”amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue
175. Use of methylene blue and bicarbonate in ifosfamide-related CNS toxicity: Case report
176. Methylene blue for ifosfamide-associated encephalopathy
177. Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy
178. Mesna: A short review
179. Oral mesna: A review
180. Ifosfamide and mesna
181. Oxazaphosphorine toxicity reduction of mesna
182. Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer
183. Use of mesna to prevent ifosfamide-induced urotoxicity
184. Combined intravenous and oral mesna in outpatients treated with ifosfamide
185. Mesna inactivates platinum agents in vitro
186. Ifosfamide-induced nephrotoxicity in children: Critical review of predictive risk factors [electronic version]
187. Ifosfamide, mesna, and nephrotoxicity in children
188. Nephrotoxicity of ifosfamide-moving towards understanding the molecular mechanism
189. Renal dysfunctions secondary to ifosfamide treatment in children
190. Ifosfamide metabolite chloroacetaldehyde causes Fanconi Syndrome in perfused rat kidney
191. First evidence of renal biotransformation of ifosfamide to nephrotoxic metaholites
192. L-Carnitine: A way to decrease cellular toxicity of ifosfamide?
193. Increased urinary losses of carnitine during ifosfamide chemotherapy
194. Ifosfamide nephrotoxicity: Limited influence of metabolism and mode of administration during repeated therapy in paediatrics
195. Depletion of total cysteine, gluthatione, and homocysteine in plasma by ifosfamide/mesna therapy
196. Depletion of circulating cyst“e”ine by oral and intravenous mesna
197. Ifosfamide with mesna uroprotection in the management of lung cancer
198. The efficacy and safety of GR38023F in the prophylaxis of ifosfamide-induced nausea and vomiting
199. Hypersensitivity after ifosfamide administration
200. Ifosfamide cardiotoxicity in humans
201. Interstitial pneumonitis associated with ifosfamide therapy
202. Development of new cancer chemoprevention agents: Role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring
203. Cyclophosphamide pharmacokinetics: Correlation with cardiotoxicity and tumor response
204. Correlation of highdose cyclophosphamide, cisplatin, and carmustine pharmacokinetics to response and toxicity in patients with primary breast cancer
205. Pharmacokinetics of alkylating agents
206. High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: Correlation of plasma drug levels with renal toxicity
207. Pharmacokinetics of 'activated' cyclophosphamide and therapeutic efficacies
208. Oxazaphosphorines: Cyclophosphamide and ifosfamide
209. Leukocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF
210. The leukocyte nadir, a predicator of chemotherapy efficacy